文献速递临床试验与 GCP流行病学与生物统计

COVID-19大流行对ICU临床试验的影响:一个研究团队的经历描述

The impact of the COVID-19 pandemic on ICU clinical trials: a description of one research team's experience.
PubMed 文献 · Trials · 2023-05-11

该描述性回顾研究利用某非COVID-19母临床试验的详细筛选日志与现场笔记,比较了疫情前(2018年8月27日至2020年3月15日,筛选2976例)与疫情期间(2020年3月16日至2022年2月28日,筛选3912例)在两个学术医学中心及一家社区医院ICU的筛选与入组情况,发现疫情前入组55例、疫情期间入组45例,尽管因低血压、认知障碍/痴呆、昏迷或化学性瘫痪导致的筛选失败显著减少。研究揭示了研究人员的疫情负担导致入组下降,作者建议研究者主动管理人力和财务资源以成功开展ICU临床试验。

要点

  • 疫情前筛选2976例、入组55例;疫情期间筛选3912例、入组45例,入组人数减少。
  • 疫情期间因低血压、认知障碍/痴呆、昏迷或化学性瘫痪导致的筛选失败显著减少。
  • 拒绝知情同意的原因在疫情前后无显著差异。

核心结论

  • 母临床试验虽保持开放,但疫情期间累积因素对试验产生不利影响,入组患者更少。
  • 疫情对研究人员、临床医生和患者/家属造成的人力代价要求研究者主动管理这些挑战,包括仔细监督人力和财务资源。

研究设计与样本

  • 描述性、回顾性设计,使用某母临床试验的详细筛选日志定量数据及现场笔记定性观察。
  • 母临床试验为两中心试验(n=190),旨在检验机械通气ICU患者自我给药镇静治疗对焦虑和谵妄发生率的疗效。
  • 筛选两个学术医学中心(名称因设盲删除)及明尼苏达州一家社区医院的ICU,每日筛查警觉患者(RASS -2至+1)、能遵循指令、血流动力学稳定且握力足以按下按钮装置者。
  • 疫情前时间段为2018年8月27日至2020年3月15日(筛选2976例),疫情期间为2020年3月16日至2022年2月28日(筛选3912例)。

主要发现

  • 疫情前入组55例,疫情期间入组45例。
  • 疫情期间因低血压、认知障碍/痴呆、昏迷或化学性瘫痪导致的筛选失败显著减少。
  • 拒绝知情同意的原因无显著差异。
  • 研究揭示研究人员的疫情负担导致入组下降。

临床怎么用

  • 作者认为研究者应主动管理疫情带来的挑战,包括仔细监督人力和财务资源,以成功开展ICU临床试验。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Disruptions to clinical trials conducted in the intensive care unit (ICU) due to the severe acute respiratory syndrome coronavirus 2 (SARS-CoV2; coronavirus disease 2019 [COVID-19]) pandemic included fewer new trials activated and more trials stopped. While a number of ongoing, non-COVID-19 clinical trials remained open to enrollment, the direct impact of the pandemic on ICUs instilled chaos in this already challenging environment. The numerous challenges need to be reported so investigators can proactively plan and manage these myriad challenges. Thus, the purpose of this study was to describe the impact of the COVID-19 pandemic on screening and accrual for a non-COVID-19 parent clinical trial enrolling critically ill ICU patients receiving mechanical ventilatory support. METHODS: A descriptive, retrospective design using quantitative data from detailed screening logs and qualitative observations with field notes from a parent clinical trial were used to address the objectives. The primary aims of the two-site parent clinical trial (n = 190) are to test the efficacy of self-administration of sedative therapy by mechanically ventilated ICU patients on anxiety and delirium occurrence. ICUs from two academic medical centers [names removed for blinding] plus a community hospital in Minnesota were screened daily for alert patients (Richmond Agitation Sedation Scale [RASS] - 2 to + 1), following commands, hemodynamically stable with sufficient hand grip strength to depress a push-button device. Screening data were summarized based on the primary reason patients were not enrolled (screen failures, declinations of consent). Descriptive statistics (frequencies, percentages), chi-square, and Fisher's Exact test were used to describe the data and to determine any differences among distributions of screening failures and recruitment declinations during the defined pre-pandemic (August 27, 2018-March 15, 2020, 2976 screened patients) and pandemic timeframes (March 16, 2020-February 28, 2022, 3912 screened patients). Qualitative data from varied sources such as screening logs, institutional email communications, staff field notes, and research team meeting minutes were summarized into themes. RESULTS: Despite significantly fewer screen failures due to hypotension, cognitive impairment/dementia, coma, or chemical paralysis with 938 additional patients on the screening log, more were accrued pre-pandemic (n = 55) than during the pandemic period (n = 45); declination reasons were non-significant. Pandemic burdens experienced by study personnel, ICU care providers, and patients/families were revealed that attributed to decreased accrual. CONCLUSIONS: While the parent clinical trial remained opened, cumulative factors adversely impacted the trial during the pandemic period with fewer patients accrued. The human toll of the pandemic on research staff, clinicians, and patients/family members demands that investigators be proactive in managing these challenges to conduct ICU clinical trials successfully, including careful oversight of human and financial resources. TRIAL REGISTRATION: ClinicalTrials.gov NCT#02,819,141 Registered 29 June 2016.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Chlan LL, Tracy MF, Ask J, et al. The impact of the COVID-19 pandemic on ICU clinical trials: a description of one research team's experience. Trials. 2023. PMID: 37165383. doi:10.1186/s13063-023-07355-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。